Endometrial Cancer: What Is New in Adjuvant and Molecularly Targeted Therapy?

@inproceedings{Zagouri2010EndometrialCW,
  title={Endometrial Cancer: What Is New in Adjuvant and Molecularly Targeted Therapy?},
  author={Flora Zagouri and George Bozas and Eftichia Kafantari and Marinos L. Tsiatas and Nikitas Nikitas and Meletios-A. Dimopoulos and Christos Papadimitriou},
  booktitle={Obstetrics and gynecology international},
  year={2010}
}
Endometrial cancer is the most common gynaecological cancer in western countries. Radiotherapy remains the mainstay of postoperative management, but accumulating data show that adjuvant chemotherapy may display promising results after staging surgery. The prognosis of patients with metastatic disease remains disappointing with only one-year survival. Progestins represent an effective option, especially for those patients with low-grade estrogen and/or progesterone receptor positive disease… CONTINUE READING